Form 4: ClearPoint Neuro Executive Jeremy Stigall Reports Tax Withholding Transaction

ClearPoint Neuro's Chief Business Officer, Jeremy Stigall, reports a transaction involving the delivery of shares to cover tax withholding obligations related to the vesting of restricted stock.

Summary

• On February 22, 2025, Jeremy Stigall, Chief Business Officer of ClearPoint Neuro, Inc., reported a transaction on Form 4.
• The transaction involved the disposition of 908 shares of common stock at a price of $16.72 per share.
• These shares were used to satisfy tax withholding obligations related to the vesting of restricted stock.
• Following the transaction, Stigall directly owns 47,615 shares of ClearPoint Neuro common stock.
• Stigall has granted power of attorney to Joseph M. Burnett, Ellisa Cholapranee, Danilo D'Alessandro, Jeremy Stigall, and Mazin Sabra to handle Section 16 reporting requirements.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, indicating standard corporate governance practices. The transaction itself is neutral, reflecting tax obligations rather than a strategic decision about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC for insiders of publicly traded companies, providing transparency into their transactions in the company's stock.

Key Dates